Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tweak API Scheme For ‘Self-Reliant’ India, Says Industry

Dr Reddy’s Considers Investment

Executive Summary

Companies including Dr Reddy’s will consider investing in new API units if the Indian government tweaks its incentive scheme to permit exports of surplus production. Other suggested changes to the $1.3bn stimulus, aimed at enhancing the country's medicines security, include extending incentives to brownfield expansions and removing restrictions on a change in product mix.

You may also be interested in...



Will The $3bn Stimulus Amid COVID-19 Place Indian Cos Among Goliaths?

Following an INR69bn incentive scheme for APIs, the Indian government has come up with an INR150bn scheme for formulations and more. Will this $3bn push prove to be the one that companies like Sun Pharma and Aurobindo, currently at 36 and 48 respectively in Scrip 100 rankings, need to break into the top league?

Webinar Recording: India Supply Chain Issues Against The Backdrop Of COVID-19

Join Anju Ghangurde and Vibha Ravi in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series on COVID-19: Lessons Learned And A Path Forward.

Webinar Recording: India Supply Chain Issues Against The Backdrop Of COVID-19

Join Anju Ghangurde and Vibha Ravi in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series on COVID-19: Lessons Learned And A Path Forward.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel